UP!

CTLT $84.32   View long term graphs

Catalent, Inc.
Type
Public company
Traded as NYSE: CTLT
S&P 400 Component
Industry Pharmaceutical
Biotechnology
Predecessor Cardinal Health PTS
Founded 2007
Headquarters Somerset, New Jersey, USA
Number of locations
33
Key people
John Chiminski
(President, CEO),
Matthew Walsh
(Executive Vice President, CFO)
Services Drug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain solutions, regulatory consulting
Revenue US$1.83 billion (2014)
Operating income
US $374.4 million (2014)
Net income
US $142.4 million (2014)
Number of employees
8,300 (2014)
Website www.catalent.com

Catalent, Inc. (Catalent Pharma Solutions) is a global provider of drug delivery technology and development solutions for drugs, biologics and consumer health products. Headquartered in Somerset, New Jersey, Catalent operates 33 locations across five continents, producing more than 70 billion doses annually for nearly 7,000 customer products.

Originally created through a series of acquisitions by Cardinal Health Inc., Catalent became independent in 2007. Catalent promotes its ability to increase customers' speed to market and its participation in nearly half of new drug entities approved by the Food and Drug Administration in the last decade. The company currently holds approximately 1,300 patents and patent applications and continues to expand its offerings through investments in emerging technologies. In its fiscal year 2014 (ending June 30), Catalent’s customers included 83 of the top 100 branded drug marketers, 20 of the top 25 generics marketers, 38 of the top 50 biologics marketers, and 19 of the top 20 consumer health marketers globally. On July 31, 2014, Catalent became a public company and is listed on the New York Stock Exchange (NYSE: CTLT).

In 1996, Cardinal Health acquired PCI (Headquarters: Philadelphia, Pennsylvania). PCI (Packaging Coordinators Inc.) is a pharmaceutical contract packing service for commercial and clinical packaging. In 1998, Cardinal Health acquired R.P. Scherer Corporation (Headquarters: Troy, Michigan). Robert Pauli Scherer founded the R.P. Scherer Corporation to commercialize his innovation of softgel encapsulation using the rotary die production process. In 1999, Cardinal Health acquired Automatic Liquid Packaging, Inc. (Headquarters: Woodstock, Ill.), whose Blow-Fill-Seal Technology allowed Cardinal to enter the sterile product market. Cardinal Health also acquired International Processing Corporation (Headquarters: Winchester, Kentucky) for its advanced controlled drug release and coating manufacturing expertise.

In 2002, Cardinal Health acquired Magellan Laboratories Inc., a company that specialized in product development expertise. In 2003, Cardinal Health acquired Gala Biotech (Headquarters: Madison, Wisconsin). Gala Biotech had established technologies surrounding gene insertion and the production of pharmaceutical proteins, which became GPEx® Technology. In the same year, Cardinal Health also acquired Intercare Group PLC, broadening its global capabilities in Europe. In 2004-2006, Cardinal Health further expanded its reach in biotechnology and pharmaceutical markets through multiple other acquisitions.

In 2007, the Pharmaceutical Technologies and Services segment of Cardinal Health was purchased by Blackstone Group and re-branded as Catalent Pharma Solutions.

In 2011, the Company acquired the molecular optimization platform OptiForm®, from GlaxoSmithKline. In 2012, Catalent acquired Aptuit, a clinical supply solutions company. As part of the deal, Catalent gained three sites in the United States, two sites in the United Kingdom and one in Singapore. Catalent also acquired all remaining shares for the R.P Scherer site in Eberbach, Germany. In 2013, Catalent Pharmaceutical Solutions continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology Co., a China-based company, and Relthy Laboratories in Brazil. Also in 2013, Catalent created a new business unit, Advanced Delivery Technologies which focuses on innovative and proven drug delivery technologies, optimizing the company’s multiple technologies, cross-platform R&D solutions and global commercial manufacturing network. This is the current structure of Catalent’s business which includes softgel technologies, advanced delivery technologies and development & clinical services business units.

Catalent announced its initial public offering on July 30, 2014. After raising more than $870 million, Catalent became a publicly traded company on the New York Stock Exchange (NYSE). The company priced its 42.5 million shares of common stock at $20.50 apiece, with a market capitalization of $2.4 billion. The shares began trading on the NYSE on July 31, 2014, under the ticker symbol CTLT, and the offering closed on August 1, 2014. The proceeds of the offering went to the redemption of more than $800 million of Catalent’s outstanding debt. “This will allow the company to significantly reduce its interest expense, enable future potential internal and external growth strategies, and to continue our growth-biased investments into new technologies, capabilities, global development and manufacturing facilities and capacity,” a company statement reported.

In September 2016, the company acquired the contract drug development and clinical manufacturing company, which specializes in early stage development and spray drying: Pharmatek Laboratories.

In November 2016, the company agreed to acquire Canadian based Accucaps Industries. Both the Strathroy, ON and Windsor, ON locations will become the 12th and 13th Softgel Technology Facilities under the Catalent name.

Catalent's brand currently owns and operates the following drug delivery technologies:

Predevelopment Technologies

Oral Drug Delivery Technologies

Sterile Technologies

Biologics

Catalent has designated the following locations as a "Center of Excellence" with the following specializations:

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q1 2021 2020-11-03 Future report Set alerts
Q4 2020 2020-08-31 0.90 0.85
Q3 2020 2020-05-05 0.50 0.08
Q2 2020 2020-02-03 0.45 0.23
Q1 2020 2019-11-05 0.26 -0.05
Q4 2019 2019-08-27 0.70 0.44
Q3 2019 2019-05-07 0.49 0.22
Q2 2019 2019-02-05 0.45 0.33
Q1 2019 2018-11-06 0.28 -0.10
Q4 2018 2018-08-28 0.67 0.61

Ratings

2016-06-21 Upgrade Wells Fargo Market Perform to Outperform
2016-06-21 Upgrade Wells Fargo & Co. Market Perform to Outperform
2016-06-20 Upgrade Bank of America Neutral to Buy
2016-06-20 Upgrade Bank of America Corp. Neutral to Buy
2016-05-05 Downgrade Bank of America Buy to Neutral
2016-05-05 Downgrade William Blair Outperform to Market Perform
2016-04-21 Downgrade Morgan Stanley Overweight to Equal Weight $30.00
2016-02-11 Reiterated Rating Bank of America Buy $31.00 to $28.00
2016-02-10 Lower Price Target JPMorgan Chase & Co. Overweight $32.00 to $28.00
2016-02-10 Lower Price Target Jefferies Group Hold $29.00 to $22.00
2016-02-10 Lower Price Target Deutsche Bank Hold $31.00 to $24.00
2016-02-10 Reiterated Rating Piper Jaffray Outperform $30.50 to $29.00
2016-02-10 Lower Price Target Deutsche Bank AG Hold $31.00 to $24.00
2016-02-10 Reiterated Rating Piper Jaffray Cos. Outperform $30.50 to $29.00
2015-12-28 Downgrade Wells Fargo Outperform to Hold
2015-12-22 Downgrade Wells Fargo Outperform to Market Perform
2015-12-09 Downgrade Raymond James Outperform to Market Perform
2015-12-09 Downgrade Raymond James Financial Inc. Outperform to Market Perform
2015-11-04 Lower Price Target Deutsche Bank Hold $33.00 to $31.00
2015-11-04 Lower Price Target Piper Jaffray $32.00 to $30.50
2015-09-10 Reiterated Rating Deutsche Bank Hold $33.00
2015-09-10 Downgrade Jefferies Group Buy to Hold $32.00 to $29.00
2015-09-06 Reiterated Rating William Blair Buy
2015-09-03 Boost Price Target JPMorgan Chase & Co. Overweight $35.00 to $36.00
2015-09-03 Reiterated Rating Bank of America Buy $35.00 to $36.00
2015-05-09 Reiterated Rating Raymond James Outperform $31.00 to $33.00
2015-02-18 Boost Price Target Jefferies Group Buy $28.50 to $32.00
2015-02-12 Boost Price Target Deutsche Bank Hold $26.00 to $33.00
2015-01-06 Boost Price Target JPMorgan Chase & Co. Overweight $28.00 to $32.00
2014-11-14 Reiterated Rating Jefferies Group Buy $26.50 to $28.50
2014-11-14 Reiterated Rating Deutsche Bank Hold $25.00 to $26.00
2014-11-14 Boost Price Target Bank of America Buy $26.00 to $28.00
2014-09-09 Initiated Coverage William Blair Outperform
2014-09-09 Initiated Coverage Morgan Stanley Overweight $27.00
2014-09-09 Initiated Coverage Wells Fargo & Co. Outperform
2014-09-09 Initiated Coverage Raymond James Outperform $27.00
2014-09-09 Initiated Coverage Goldman Sachs Neutral
2014-09-09 Initiated Coverage Bank of America Buy $26.00
2014-09-09 Initiated Coverage Piper Jaffray Overweight $28.00
2014-09-09 Initiated Coverage JPMorgan Chase & Co. Overweight $28.00
2014-09-09 Initiated Coverage Deutsche Bank Hold $25.00
2014-09-09 Initiated Coverage Jefferies Group Buy $26.50
2014-09-09 Initiated Coverage Wells Fargo Outperform
2014-09-09 Initiated Coverage Goldman Sachs Group Inc. Neutral
2016-06-21 Upgrade Wells Fargo Market Perform to Outperform
2016-06-21 Upgrade Wells Fargo & Co. Market Perform to Outperform
2016-06-20 Upgrade Bank of America Neutral to Buy
2016-06-20 Upgrade Bank of America Corp. Neutral to Buy
2016-05-05 Downgrade Bank of America Buy to Neutral

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks

Comments